ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera
A total of 111 patients were randomized and the last patient was enrolled on June 21, 2024. As of November 12, 2024, the discontinuation rate was 14.4%, and 16 patients (14.4%) completed the study. The study is expected to be completed in the summer of 2025. This is the first prospective trial comparing two dosing regimens of ropeg. The results will inform the optimal treatment strategy for patients with PV.
Authors
- Stephen T. Oh (ORCID: https://orcid.org/0000-0002-8564-5400)
- Albert Qin (ORCID: https://orcid.org/0000-0001-7610-084X)
- Sunil Babu (ORCID: https://orcid.org/0000-0001-5085-6905)
- Rupali Roy Bhave (ORCID: https://orcid.org/0000-0003-2252-1547)
- Prithviraj Bose (ORCID: https://orcid.org/0000-0002-4343-5712)
- Pierre Villeneuve (ORCID: https://orcid.org/0000-0002-0944-1721)
- Stephanie J. Lee (ORCID: https://orcid.org/0000-0003-2600-6390)
- Sonia Cerquozzi (ORCID: https://orcid.org/0000-0001-9027-1776)
- Luke Fletcher (ORCID: https://orcid.org/0000-0002-7238-3480)
- Hayman Salib
- Brandi Reeves (ORCID: https://orcid.org/0000-0002-2106-3698)
- Christopher Hillis
- Swati Goel (ORCID: https://orcid.org/0000-0001-7647-8922)
- Oleh Zagrijtschuk
- Firas El Chaer (ORCID: https://orcid.org/0000-0001-9596-0714)
- Victor Priego
- Tsewang Tashi (ORCID: https://orcid.org/0000-0002-2785-866X)
- Lynda Foltz
- Shireen Sirhan (ORCID: https://orcid.org/0000-0003-4957-4307)
- Christopher B. Benton (ORCID: https://orcid.org/0000-0003-3645-148X)
- Abdulraheem Yacoub (ORCID: https://orcid.org/0000-0001-5293-4620)
- John O Mascarenhas (ORCID: https://orcid.org/0000-0002-8400-0483)
- Ghaith F. Abu-Zeinah (ORCID: https://orcid.org/0000-0002-1881-3670)
- Lucia Masárová (ORCID: https://orcid.org/0000-0001-6624-4196)
- Dawn Maze (ORCID: https://orcid.org/0000-0002-4598-9380)
- Henry Castro
- Hana Safah
Institutions
- University of North Carolina at Chapel Hill (US)
- Atrium Health Wake Forest Baptist (US)
- St. Michael's Hospital (CA)
- Albert Einstein College of Medicine (US)
- Our Lady of the Lake Regional Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- Washington University in St. Louis (US)
- Cornell University (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Jewish General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Fort Wayne Medical Institute (US)
- Institute of Cancer Research (CA)
- Sarah Cannon (US)
- Acceleron Pharma (United States) (US)
- Radiology Associates (US)
- Tisch Hospital (US)
- Center for Cancers and Blood Disorders (US)
- Rocky Mountain Cancer Centers (US)
- St. Paul's Hospital (CA)
- Cellular Therapeutics (United Kingdom) (GB)
- Weill Cornell Medicine (US)
- McGill University (CA)
- University of Virginia (US)
- McMaster University (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1159/000544818
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63